Hamilton Thorne Announces Voting Results of 2024 Annual Meeting
12 June 2024 - 6:30AM
Hamilton Thorne Ltd. (TSX: HTL) ("Hamilton Thorne" or the
"Company"), a leading provider of precision instruments,
consumables, software, and services to the Assisted Reproductive
Technologies ("ART") research and cell biology markets, today
announced the voting results from its Annual General and Special
Meeting of Shareholders held on Tuesday June 11, 2024 (the
“Meeting”). A total of 99,394,475 common shares were voted at the
Meeting, representing 64.65% of the votes attached to all
outstanding shares.
1. All nine nominees were elected to the Hamilton Thorne Board
of Directors, and each director elected will continue to hold
office until the Company’s next annual meeting of shareholders, or
until the director resigns or a successor is elected or appointed.
The voting results for directors were as follows:
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
Karen Firestone |
98,164,035 |
99.97% |
27,800 |
0.03% |
Feng Han |
98,163,535 |
99.97% |
28,300 |
0.03% |
Bruno Maruzzo |
94,556,717 |
96.30% |
3,635,118 |
3.70% |
Robert J. Potter |
94,432,052 |
96.17% |
3,759,783 |
3.83% |
Marc H. Robinson |
98,163,535 |
99.97% |
28,300 |
0.03% |
David B. Sable |
98,163,535 |
99.97% |
28,300 |
0.03% |
Daniel K. Thorne |
94,591,532 |
96.33% |
3,600,303 |
3.67% |
Ekatarina Torchilin |
97,735,452 |
99.54% |
456,383 |
0.46% |
David Wolf |
97,735,752 |
99.54% |
456,083 |
0.46% |
|
|
|
|
|
2. Shareholders re-appointed MNP LLP as auditor of the
Company, with 99.55% of all votes cast in favor.
3. Shareholders approved the proposed share consolidation
resolution as described in the Circular, with 99.92% of all votes
cast in favor.
4. Shareholders approved the proposed Long Term Equity Incentive
Plan amendment resolution as described in the Circular, with 94.33%
of all votes cast in favor.
About Hamilton Thorne Ltd.
(www.hamiltonthorne.ltd)
Hamilton Thorne is a leading global provider of precision
instruments, consumables, software and services that reduce cost,
increase productivity, improve results and enable breakthroughs in
Assisted Reproductive Technologies (ART), research, and cell
biology markets. Hamilton Thorne markets its products and services
under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech
Laboratories, Tek-Event, Microptic, and Gynetics brands, through
its growing sales force and distributors worldwide. Hamilton
Thorne’s customer base consists of fertility clinics, university
research centers, animal breeding facilities, pharmaceutical
companies, biotechnology companies, and other commercial and
academic research establishments.
For more information, please contact:
Kate Torchilin, President & CEOHamilton Thorne
Ltd.978-921-2050ir@hamiltonthorne.ltd |
|
Francesco Fragasso, CFOHamilton Thorne
Ltd.978-921-2050ir@hamiltonthorne.ltd |
|
|
|
Glen Akselrod Bristol Investor Relations 905-326-1888
glen@bristolir.com |
|
|
|
|
|
Hamilton Thorne (TSX:HTL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hamilton Thorne (TSX:HTL)
Historical Stock Chart
From Nov 2023 to Nov 2024